FDA
-
-
-
-
-
-
-
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
-
-
-
-
-
-
-
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
-
-
-
-
-
-
-
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
-
-
-
-
-
-
-
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volun
-
-
-
-
-
-
-
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
-
-
-
-
-
-
-
PureTech Announces Board Change
-
322,999 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
